Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

GLP-1 weight-loss drugs alleviate obesity as well as provide other health benefits. Yet they are also the focus of ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

Large employers could spend as much as an additional 7.8% in health costs next year, according to a Business Group on Health survey.

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

Sen. Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they would expand ...

A recent survey by Zimmer Biomet indicated that some obese patients may be eligible for surgery following weight loss due to the use of GLP-1 medications, but respondents did not feel that these ...

"All we are saying [to Novo Nordisk] is, Treat the American people the same way that you treat people all over the world.

Here are five key takeaways: During the hearing, Novo Nordisk CEO Lars Fruergaard Jørgensen attributed the high prices of drugs such as Ozempic and Wegovy to PBMs, arguing that "a high list price is ...